
DelistingNov 20, 2026, 05:01 PM
Compass Therapeutics Faces Nasdaq Delisting Warning Over Low Stock Price
AI Summary
Compass Therapeutics, Inc. received a deficiency letter from Nasdaq indicating its common stock has traded below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has 180 days, until May 18, 2027, to regain compliance. Failure to do so could lead to a second 180-day period, with potential delisting if compliance is not achieved. Compass is considering options, including a reverse stock split, to meet the requirement.
Key Highlights
- Compass Therapeutics received a Nasdaq deficiency letter for failing to meet the $1.00 minimum bid price requirement.
- The company has 180 days, until May 18, 2027, to regain compliance with the Minimum Bid Price Requirement.
- Compliance can be achieved if the stock closes at $1.00 or more for 10 consecutive business days before May 18, 2027.
- A second 180-day compliance period may be granted if the company meets other listing standards and intends to cure the deficiency, potentially via a reverse stock split.
- Failure to regain compliance by the deadline could result in delisting, with a possibility to appeal to a Nasdaq Hearings Panel.
Price Impact
More from CMPX